AR105568A1 - Un método para provocar una respuesta inmunitaria en un sujeto receptor de especie porcina - Google Patents
Un método para provocar una respuesta inmunitaria en un sujeto receptor de especie porcinaInfo
- Publication number
- AR105568A1 AR105568A1 ARP160102348A ARP160102348A AR105568A1 AR 105568 A1 AR105568 A1 AR 105568A1 AR P160102348 A ARP160102348 A AR P160102348A AR P160102348 A ARP160102348 A AR P160102348A AR 105568 A1 AR105568 A1 AR 105568A1
- Authority
- AR
- Argentina
- Prior art keywords
- pig
- immunomodulatory composition
- nucleic acid
- administering
- cholesterol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Reivindicación 1: Un método para provocar una respuesta inmunitaria en un sujeto receptor de especie porcina que comprende: administrar una cantidad efectiva de una composición inmunomoduladora a un sujeto de la especie porcina, donde la composición inmunomoduladora comprende una secuencia de ácidos nucleicos que comprende al menos un motivo CpG inmunoestimulante, al menos un motivo CpG no inmunoestimulante y un liposoma catiónico. Reivindicación 3: El método de reivindicación 1, donde el vehículo de suministro de liposoma comprende pares de lípidos que se seleccionan del grupo que consiste en cloruro de N-[1-(2,3-dioleiloxi)propil]-N,N,N-trimetilamonio (DOTMA) y colesterol; cloruro de N-[1-(2,3-dioleiloxi)propil]-N,N,N-trimetilamonio (DOTAP) y colesterol; cloruro de 1-[2-(oleoyloxi)etil]-2-oleil-3-(2-hidroxietil)imidazolinio (DOTIM) y colesterol; y bromuro dedimetildioctadecilamonio (DDAB) y colesterol. Reivindicación 4: El método de la reivindicación 1, donde la composición inmunomoduladora comprende adicionalmente o se administra en combinación con un agente biológico. Reivindicación 7: El método de la reivindicación 1, donde la composición inmunomoduladora comprende una secuencia de ácido nucleico con al menos 80% de identidad de secuencia con una secuencia que se selecciona del grupo que consiste en SEQ ID Nº 1, SEQ ID Nº 2, SEQ ID Nº 3 y SEQ ID Nº 4. Reivindicación 11: Un método para mejorar la producción de porcinos de granja que comprende administrar a un porcino una composición inmunomoduladora, donde la composición inmunomoduladora comprende una secuencia de ácidos nucleicos que comprende al menos un motivo CpG inmunoestimulante y un liposoma catiónico. Reivindicación 12: Un método para mejorar la supervivencia de porcinos de granja que comprende administrar a un porcino una composición inmunomoduladora, donde la composición inmunomoduladora comprende una secuencia de ácidos nucleicos que comprende al menos un motivo CpG inmunoestimulante y un liposoma catiónico. Reivindicación 13: Un método para reducir la diarrea en un cerdo que comprende administrar al cerdo una cantidad eficaz de una composición inmunomoduladora, donde el inmunomodulador comprende: a) un vehículo de suministro de lípidos catiónicos; y b) una molécula de ácido nucleico que no codifica un inmunógeno, donde tal administración reduce la diarrea en tal cerdo luego de una estimulación con Escherichia coli. Reivindicación 19: Un método para aumentar el aumento de peso en un cerdo que comprende administrar al cerdo una composición inmunomoduladora, donde el inmunomodulador comprende: a) un vehículo de suministro de lípidos catiónicos; y b) una molécula de ácido nucleico que no codifica un inmunógeno, donde tal administración aumenta el peso de tal cerdo luego de una estimulación con el virus de síndrome respiratorio y reproductivo porcino (PRRSV).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562199848P | 2015-07-31 | 2015-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR105568A1 true AR105568A1 (es) | 2017-10-18 |
Family
ID=56682095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160102348A AR105568A1 (es) | 2015-07-31 | 2016-08-01 | Un método para provocar una respuesta inmunitaria en un sujeto receptor de especie porcina |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11439703B2 (es) |
| EP (1) | EP3328424A1 (es) |
| JP (1) | JP2018521109A (es) |
| KR (1) | KR20180036765A (es) |
| CN (1) | CN108025062A (es) |
| AR (1) | AR105568A1 (es) |
| AU (1) | AU2016302436B2 (es) |
| BR (1) | BR112018002107A2 (es) |
| CA (1) | CA2993883A1 (es) |
| CL (1) | CL2018000253A1 (es) |
| HK (1) | HK1255052A1 (es) |
| IL (1) | IL256984A (es) |
| MX (1) | MX2018001251A (es) |
| PH (1) | PH12018500201A1 (es) |
| SG (1) | SG10202000891UA (es) |
| TW (1) | TW201718001A (es) |
| WO (1) | WO2017021266A1 (es) |
| ZA (1) | ZA201801338B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019001599A2 (pt) | 2016-07-26 | 2019-10-01 | Bayer Animal Health Gmbh | fertilidade aumentada em espécies bovinas |
| CA3197650A1 (en) * | 2020-10-02 | 2022-04-07 | Celsion Corporation | Polynucleotide vaccines and methods of using the same |
| WO2023224882A1 (en) * | 2022-05-17 | 2023-11-23 | Elanco Us Inc. | Methods for predicting efficacy of a modified live porcine reproductive and respiratory syndrome virus (prrsv) vaccine |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| ATE370740T1 (de) * | 1997-05-20 | 2007-09-15 | Ottawa Health Research Inst | Verfahren zur herstellung von nukleinsäurekonstrukten |
| US20040247662A1 (en) | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
| US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
| US6693086B1 (en) | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| ATE549032T1 (de) | 1999-03-26 | 2012-03-15 | Vical Inc | Adjuvanzverbindungen zur verbesserung von immunreaktionen auf polynukleotid-basierten impfstoffen |
| HU221664B1 (hu) * | 1999-03-31 | 2002-12-28 | MTA Állatorvostudományi Kutatóintézete | Élő, szájon át adható Escherichia coli vakcina készítésére alkalmas törzs a sertések választási hasmenésének megelőzésére és a törzs előállítására alkalmas eljárás |
| US20040002472A1 (en) | 2000-01-21 | 2004-01-01 | Audonnet Jean-Christophe Francis | Vaccination or immunization using a prime-boost regimen |
| CA2437899C (en) * | 2001-02-13 | 2012-05-15 | Gregory M. Glenn | Vaccine for transcutaneous immunization against etec-caused traveler's diarrhea |
| PL1605971T3 (pl) | 2003-03-26 | 2010-10-29 | Wyeth Llc | Kompozycja immunogenna i sposoby |
| AU2004280143A1 (en) | 2003-10-11 | 2005-04-21 | Tekmira Pharmaceuticals Corporation | Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
| US20050181035A1 (en) | 2004-02-17 | 2005-08-18 | Dow Steven W. | Systemic immune activation method using non CpG nucleic acids |
| US20060135457A1 (en) | 2004-08-13 | 2006-06-22 | Yvonne Paterson | Methods for constructing antibiotic resistance free vaccines |
| EP2249843A4 (en) * | 2008-02-24 | 2013-05-08 | Us Gov Health & Human Serv | USE OF IMMUNOGENIC COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF PATHOGENIC INFECTIONS |
| WO2009120811A1 (en) | 2008-03-25 | 2009-10-01 | Juvaris Biotherapeutics, Inc. | Enhancement of an immune response by administration of a cationic lipid-dna complex (cldc) |
| US8251111B2 (en) | 2008-09-18 | 2012-08-28 | Premium Balloon Accessories, Inc. | Balloon inflator |
| US8465748B2 (en) * | 2009-03-30 | 2013-06-18 | Matthias Giese | Vaccine compositions and methods containing an immunogen derived from equine arteritis virus |
| EP2429581B1 (en) * | 2009-05-14 | 2015-08-05 | Bayer Intellectual Property GmbH | Enhanced immune response in avian species |
| WO2012084951A1 (en) | 2010-12-22 | 2012-06-28 | Bayer Animal Health Gmbh | Enhanced immune response in bovine species |
| MX2016010993A (es) * | 2014-02-28 | 2017-05-01 | Bayer Animal Health Gmbh | Plasmidos inmunoestimuladores. |
-
2016
- 2016-07-28 SG SG10202000891UA patent/SG10202000891UA/en unknown
- 2016-07-28 JP JP2018504671A patent/JP2018521109A/ja active Pending
- 2016-07-28 BR BR112018002107A patent/BR112018002107A2/pt active Search and Examination
- 2016-07-28 MX MX2018001251A patent/MX2018001251A/es unknown
- 2016-07-28 CN CN201680057074.6A patent/CN108025062A/zh active Pending
- 2016-07-28 KR KR1020187006085A patent/KR20180036765A/ko unknown
- 2016-07-28 WO PCT/EP2016/067971 patent/WO2017021266A1/en active Application Filing
- 2016-07-28 AU AU2016302436A patent/AU2016302436B2/en active Active
- 2016-07-28 US US15/748,444 patent/US11439703B2/en active Active
- 2016-07-28 EP EP16750416.6A patent/EP3328424A1/en not_active Withdrawn
- 2016-07-28 TW TW105123924A patent/TW201718001A/zh unknown
- 2016-07-28 CA CA2993883A patent/CA2993883A1/en not_active Abandoned
- 2016-08-01 AR ARP160102348A patent/AR105568A1/es unknown
-
2018
- 2018-01-17 IL IL256984A patent/IL256984A/en unknown
- 2018-01-25 PH PH12018500201A patent/PH12018500201A1/en unknown
- 2018-01-29 CL CL2018000253A patent/CL2018000253A1/es unknown
- 2018-02-27 ZA ZA2018/01338A patent/ZA201801338B/en unknown
- 2018-11-07 HK HK18114176.7A patent/HK1255052A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12018500201A1 (en) | 2018-07-30 |
| KR20180036765A (ko) | 2018-04-09 |
| EP3328424A1 (en) | 2018-06-06 |
| JP2018521109A (ja) | 2018-08-02 |
| US11439703B2 (en) | 2022-09-13 |
| IL256984A (en) | 2018-03-29 |
| TW201718001A (zh) | 2017-06-01 |
| WO2017021266A1 (en) | 2017-02-09 |
| BR112018002107A2 (pt) | 2018-09-25 |
| HK1255052A1 (zh) | 2019-08-02 |
| AU2016302436B2 (en) | 2022-03-03 |
| MX2018001251A (es) | 2018-03-26 |
| US20180326049A1 (en) | 2018-11-15 |
| CL2018000253A1 (es) | 2018-07-20 |
| SG10202000891UA (en) | 2020-03-30 |
| CN108025062A (zh) | 2018-05-11 |
| CA2993883A1 (en) | 2017-02-09 |
| AU2016302436A1 (en) | 2018-02-15 |
| ZA201801338B (en) | 2021-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2760790C2 (ru) | Способы получения одноцепочечной рнк | |
| AR105568A1 (es) | Un método para provocar una respuesta inmunitaria en un sujeto receptor de especie porcina | |
| CO2018005229A2 (es) | Vacuna de virus sincitial respiratorio | |
| ES2722204T3 (es) | Respuesta inmune mejorada en especies bovinas | |
| CN110195072A (zh) | 狂犬病疫苗 | |
| WO2015149944A3 (en) | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant | |
| WO2015024668A2 (en) | Respiratory syncytial virus (rsv) vaccine | |
| JP2017512202A5 (es) | ||
| TWI589298B (zh) | 陽離子之脂質疫苗組合物及其使用方法 | |
| RU2016138321A (ru) | Иммуностимулирующие плазмиды | |
| ZA202101465B (en) | Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery | |
| BR112021026439A2 (pt) | Vacina para febre suína africana | |
| TW201427686A (zh) | 改良之疫苗組成物及使用方法 | |
| CO6460752A2 (es) | Respuesta inmunitaria reforzada en especies aviares | |
| PH12019500592A1 (en) | New swine influenza vaccine | |
| CO2017001614A2 (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9 | |
| FI3244920T3 (fi) | Suu- ja sorkkatautirokote | |
| US20240075128A1 (en) | Immunogenic constructs, compositions, and methods for inducing immune response | |
| Wang et al. | Immune responses to varicella-zoster virus glycoprotein E formulated with poly (lactic-co-glycolic acid) nanoparticles and nucleic acid adjuvants in mice | |
| RU2014135522A (ru) | Промоторы для увеличенной экспрессии белка у менингококка | |
| MX2023013004A (es) | Composicion inmunogenica contra la influenza. | |
| RU2018102915A (ru) | Способы модуляции контрольных молекул цитозольной днк | |
| CN1404398B (zh) | 用于生产型动物的改良dna疫苗 | |
| PE20120116A1 (es) | Composicion inmunogenica multicomponente para la prevencion de enfermedad estreptococica beta hemolitica (bhs) | |
| ES2558157T3 (es) | Métodos para potenciar la capacidad adyuvante de las composiciones de vacunas |